Brief: Lantern Pharma’S Investigational Drug-Candidate, Lp-184, Receives Fast-Track Designation In Glioblastoma From The FDA
15/10/2024 14:09
Oct 15 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA’S INVESTIGATIONAL DRUG-CANDIDATE, LP-184,
RECEIVES FAST-TRACK DESIGNATION IN GLIOBLASTOMA FROM THE FDA
* LANTERN PHARMA INC - PHASE 1B/2A TRIAL FOR RECURRENT GBM
TO
START LATE 2024
Source text for Eikon: ID:nBw2srZjta
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview